Since FGFR4 upregulation and activation has been recently shown to confer chemoresistance in breast cancer cells [47], we asked whether inhibition of the FGFR4/FGF19 axis might enhance chemotherapy sensitivity in cancer cells. This evidence concerns the gene FGF19 and breast carcinoma.